Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.
Iovance Biotherapeutics Announces First Patient Dosed With PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the first patient was dosed, and completed the safety observation
